Back to discover

Protein / target

T-lymphocyte activation antigen CD80

Encoded byCD80P33681Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
2
Approved medicines
Open Targets target-level
View by indication →
30
Clinical trials
Antibody-tractable
Druggability
Advanced Clinical

Protein at a glance

Biological role

Receptor ligand

Strongest disease association

Hypothyroidism

Via encoding gene CD80 · Genetic evidence · score 0.70

Therapeutic position

Established drug target

Antibodies

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Costimulatory molecule that belongs to the immunoglobulin superfamily that plays an important role in T-lymphocyte activation.

View complete UniProt function annotation

Costimulatory molecule that belongs to the immunoglobulin superfamily that plays an important role in T-lymphocyte activation (PubMed:38467718). Acts as the primary auxiliary signal augmenting the MHC/TCR signal in naive T-cells by acting as a ligand for the CD28 receptor which is constitutively expressed on the cell surface of T-cells (PubMed:12196291). In turn, activates different signaling pathways such as NF-kappa-B or MAPK leading to the production of different cytokines (PubMed:10438913). Also acts as an inhibitor of T-cell activation by acting as a ligand for CTLA4, a decoy receptor, thereby blocking CD28-mediated T-cell priming (PubMed:10583602, PubMed:11279502). In addition, CD28/CD80 costimulatory signal stimulates glucose metabolism and ATP synthesis of T-cells by activating the PI3K/Akt signaling pathway (PubMed:12121659). Also acts as a regulator of PDL1/PDCD1 interactions to limit excess engagement of PDL1 and its inhibitory role in immune responses (PubMed:36727298). Expressed on B-cells, plays a critical role in regulating interactions between B-cells and T-cells in both early and late germinal center responses, which are crucial for the generation of effective humoral immune responses (By similarity)

Subcellular location

Cell membrane
Domains and Gene Ontology detail (25)

Domains & features

Ig-like V-typeIg-like C2-type

Gene Ontology

  • Ccell surface
  • Cexternal side of plasma membrane
  • Cplasma membrane
  • Cprotein complex involved in cell adhesion
  • Fcoreceptor activity
  • Freceptor ligand activity
  • Fvirus receptor activity
  • Pcell surface receptor signaling pathway
  • Pcellular response to lipopolysaccharide
  • Pimmune response
  • Pintracellular signal transduction
  • Pnegative regulation of T cell mediated immunity

288 aa · 33 kDa · 3 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell proliferation & survivalUniProtImmune signallingUniProt · GO
View supporting evidence

Cell proliferation & survival

  • ·Costimulatory molecule that belongs to the immunoglobulin superfamily that plays an impo…

Immune signalling

  • ·Costimulatory molecule that belongs to the immunoglobulin superfamily that plays an impo…
  • ·immune response
  • ·negative regulation of T cell mediated immunity
  • ·negative regulation of T cell proliferation

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Approved medicines with mapped indications

1 medicine · 2 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Delayed Graft Function1 medicine
Immune System Diseases1 medicine

2 medicines meet Open Targets' target-level approved-medicine definition; the 1 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

1

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

belatacept
Narrow target profileApprovedInhibitor

T-lymphocyte activation antigen CD80 inhibitor

Indicated for Delayed Graft Function, Immune System Diseases

Direct interaction with this protein · 1 of 2 recorded protein targets — narrow recorded profile

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene CD80

Gene-level evidence surfaced through the gene CD80that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Arthritis, Rheumatoid
0.77Well supported

Clinical evidence dominant · Open Targets 0.62

Hypothyroidism
0.70Moderately supported

Genetic evidence dominant · Open Targets 0.43

Arthritis, Juvenile
0.66Moderately supported

Clinical evidence dominant · Open Targets 0.53

Arthritis, Psoriatic
0.63Moderately supported

Clinical evidence dominant · Open Targets 0.51

Lupus Erythematosus, Systemic
0.62Moderately supported

Genetic evidence dominant · Open Targets 0.34

View evidence synthesis (5)
Arthritis, RheumatoidWell supported
0.77
agreement 0.610.93
Clinical86%Literature14%

Open Targets aggregate 0.62 · 2 independent evidence families

HypothyroidismModerately supported
0.70
agreement 0.560.84
Genetic99%Literature1%

Open Targets aggregate 0.43 · 2 independent evidence families

Arthritis, JuvenileModerately supported
0.66
agreement 0.530.80
Clinical93%RNA expression6%Literature1%

Open Targets aggregate 0.53 · 3 independent evidence families

Arthritis, PsoriaticModerately supported
0.63
agreement 0.480.79
Clinical98%Literature2%

Open Targets aggregate 0.51 · 2 independent evidence families

Lupus Erythematosus, SystemicModerately supported
0.62
agreement 0.510.72
Genetic68%Clinical18%Literature14%

Open Targets aggregate 0.34 · 3 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Arthritis, Rheumatoid0.62
Arthritis, Juvenile0.53
Arthritis, Psoriatic0.51
Immune System Diseases0.46
Hypothyroidism0.43
Neoplasms0.40
Kidney transplant0.39
Lupus Erythematosus, Systemic0.34
Lymphoma, Non-Hodgkin's0.34
Sjogren's Syndrome0.34

Drug development

3 compounds recorded · 2 approved · 1 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 1 drug that targets this protein in Forefront's canonical graph (1 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (3)
BELATACEPTApproval
ABATACEPTApproval
GALIXIMABPhase 3

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

AntibodiesStrong

Advanced Clinical and UniProt loc high conf support this modality.

Other modalitiesStrong

Approved Drug support this modality.

View underlying tractability evidence (5)
AB · Advanced ClinicalAB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMOC · Approved Drug

Raw Open Targets tractability assessment buckets, by modality.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (26)

RECRUITING · via belatacept · NCT04477629

WITHDRAWN · via belatacept · NCT02939365

COMPLETED · via belatacept · NCT01921218

ClinicalTrials.gov via the drug-target graph.

What's happening now

1

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Regulatory approval2011-06-17

    Approval: Nulojix (EMA)

    ema · regulatory · ema · via belatacept

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.